S&P Answers Frequently Asked Questions on Delphi Corp.

  • ID: 1712656
  • September 2004
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

NEW YORK (Standard & Poor's) Sept. 23, 2004-Troy, Mich.-based automotive supplier Delphi Corp. (BBB-/Negative/A-3) is expected to feel pressure on its full-year $400 million-$500 million target for net income (before restructuring charges) as a result of reduced production schedules at its major customer, General Motors Corp. (BBB/Negative/A-2) and others, according to a report published today by Standard & Poor's Ratings Services. "While there is no direct linkage between Standard & Poor's ratings of the two companies, the ratings on Delphi incorporate the health and prospects of its largest customer as well as many other factors, including its own competitive position, earnings and cash flow generation potential, and balance sheet strength," said Standard & Poor's credit analyst Martin King. "Delphi's fortunes...

Companies mentioned in this report are: Delphi Automotive LLP
Action: General Comment

Note: Product cover images may vary from those shown
2 of 3

Delphi Automotive LLP

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.